Semaglutide 2.0 mg also significantly reduced body weight versus dulaglutide 3.0 mg and 4.5 mg with ETDs of 3.29 kg and 2.57 kg respectively
Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it works through an additional mechanism that semaglutide doesnt target
SUSTAIN-6 (cardiovascular outcomes in T2D, Marso et al., NEJM 2016) reported a 26% reduction in MACE versus placebo over 104 weeks, the original cardiovascular signal that established the GLP-1 class's broader metabolic-protection profile beyond glycaemic control
Eating smaller meals, avoiding high-fat foods, and staying hydrated help manage it
They can also delay stomach emptying and cause nausea, which may result in drinking less fluid GLP-1 medications seem to lower blood pressure in some patients, which can also make patients susceptible to dizzy spells and fainting
Beyond its physical side effects, its also worth touching on adherence and relapse rates when using semaglutide for weight management
